专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06492137B1 Response element compositions and assays employing same 失效
标题翻译：响应元素组合物和采用其的测定法
公开(公告)号：US06492137B1
公开(公告)日：2002-12-10
申请号：US07672530
申请日：1991-03-19
申请人： Henry M. Sucov , Ronald M. Evans , Kazuhiko Umesono
发明人： Henry M. Sucov , Ronald M. Evans , Kazuhiko Umesono
IPC分类号： C12P2102
CPC分类号： C07K14/70567 , C07K14/721 , C12N15/85 , C12N2800/108 , C12N2830/002 , C12N2830/008 , C12N2830/30 , C12N2830/38 , C12N2830/60 , C12N2830/85 , C12Q1/6897 , G01N33/5008 , G01N33/502 , G01N33/5023 , G01N33/5041 , G01N33/743
摘要： DNA segments have been discovered, and characterized by sequence, which are response elements operative to confer responsiveness to ligands for several members of the steroid/thyroid superfamily of receptors, for the transcriptional activation and/or repression of promoters in cells. By using transcriptional control regions comprising response elements of the present invention in combination with a functional promoter, it is now possible to provide recombinant DNA vectors containing a gene, the transcription (and, thereby, also expression) of which is under the control of a promoter, the transcriptional activity of which is responsive to ligands for members of the steroid/thyroid superfamily of receptors.
摘要翻译：已经发现了DNA区段，其特征在于序列，其是作用于赋予类固醇/甲状腺超家族受体的若干成员对配体的反应性的响应元件，用于细胞中启动子的转录激活和/或抑制。通过使用包含本发明的响应元件与功能启动子组合的转录控制区，现在可以提供含有基因的重组DNA载体，其转录（并且由此也由其表达）处于一个启动子，其转录活性对受体的类固醇/甲状腺超家族成员的配体有反应。

2. 发明授权

US5091518A Beta retinoic acid response elements compositions and assays 失效
标题翻译： BETA反应性反应元素组合物和测定
公开(公告)号：US5091518A
公开(公告)日：1992-02-25
申请号：US438757
申请日：1989-11-16
申请人： Henry M. Sucov , Ronald M. Evans
发明人： Henry M. Sucov , Ronald M. Evans
IPC分类号： C07H21/04 , C07K14/705 , C12N5/10 , C12N15/09 , C12N15/85 , C12Q1/02 , G01N33/50 , G01N33/74
CPC分类号： G01N33/5023 , C07K14/70567 , C12N15/85 , G01N33/5008 , G01N33/743 , C12N2830/002 , C12N2830/60 , C12N2830/85
摘要： The present invention provide transcriptional control regions, expression vectors comprising said regions, mammalian cells transformed to transcribe and express genes from said vectors, and various methods of assaying compounds for hormone agonist or antagonist activity, all based on discovery of response elements of the .beta.-retinoic acid receptor and of the activation of said response elements in all mammalian cells without need to transform the cells to express the receptor independently of endogenous expression thereof.
摘要翻译：本发明提供了转录控制区，包含所述区域的表达载体，转化成转录和表达来自所述载体的基因的哺乳动物细胞，以及各种测定激素激动剂或拮抗剂活性化合物的方法，所有这些都是基于β - 视黄酸受体和所有哺乳动物细胞中所述应答元件的活化，而不需要转化细胞以独立于其内源性表达而表达受体。

3. 发明授权

US07189510B2 Response element compositions and assays employing same 失效
标题翻译：响应元素组合物和采用其的测定法
公开(公告)号：US07189510B2
公开(公告)日：2007-03-13
申请号：US10302557
申请日：2002-11-22
申请人： Henry M. Sucov , Ronald M. Evans , Kazuhiko Umesono
发明人： Henry M. Sucov , Ronald M. Evans , Kazuhiko Umesono
IPC分类号： C12Q1/68
CPC分类号： C07K14/70567 , C07K14/721 , C12N15/85 , C12N2800/108 , C12N2830/002 , C12N2830/008 , C12N2830/30 , C12N2830/38 , C12N2830/60 , C12N2830/85 , C12Q1/6897 , G01N33/5008 , G01N33/502 , G01N33/5023 , G01N33/5041 , G01N33/743
摘要： DNA segments have been discovered, and characterized by sequence, which are response elements operative to confer responsiveness to ligands for several members of the steroid/thyroid superfamily of receptors, for the transcriptional activation and/or repression of promoters in cells. By using transcriptional control regions comprising response elements of the present invention in combination with a functional promoter, it is now possible to provide recombinant DNA vectors containing a gene, the transcription (and, thereby, also expression) of which is under the control of a promoter, the transcriptional activity of which is responsive to ligands for members of the steroid/thyroid superfamily of receptors.
摘要翻译：已经发现了DNA区段，其特征在于序列，其是作用于赋予类固醇/甲状腺超家族受体的若干成员对配体的反应性的响应元件，用于细胞中启动子的转录激活和/或抑制。通过使用包含本发明的响应元件与功能启动子组合的转录控制区，现在可以提供含有基因的重组DNA载体，其转录（并且由此也由其表达）处于一个启动子，其转录活性对受体的类固醇/甲状腺超家族成员的配体有反应。

4. 发明授权

US06278040B1 Receptor-deficient mice and cell lines derived therefrom, and uses thereof 失效
标题翻译：受体缺陷小鼠和由其衍生的细胞系及其用途
公开(公告)号：US06278040B1
公开(公告)日：2001-08-21
申请号：US08802468
申请日：1997-02-19
申请人： Henry M. Sucov , Ronald M. Evans , Kenneth R. Chien
发明人： Henry M. Sucov , Ronald M. Evans , Kenneth R. Chien
IPC分类号： C12N1509
CPC分类号： C12N15/8509 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0375 , A61K31/203 , A61K49/0008
摘要： In accordance with the present invention, there are provided targeted loss of function mutant mice which express less than endogenous levels of at least one member of the steroid/thyroid superfamily of receptors in at least one specific tissue type. For example, mutations in the RXR&agr; gene in mouse germlines are lethal in the embryonic stage between E13.5 and E16.5 when bred to homozygosity. The major defect responsible for this lethal effect is hypoplastic development of the ventricular chambers of the heart, which is manifest as a grossly thinned ventricular wall with concurrent defects in ventricular septation. This phenotype is identical to a subset of the effects of embryonic vitamin A deficiency, and therefore establishes RXR&agr; as a genetic component of the vitamin A signaling pathway in cardiac morphogenesis. The cardiac outflow tracts and associated vessels, which are populated by derivatives of the neural crest and which are also sensitive to vitamin A deficiency, are normal in homozygous embryos, indicating the genetic independence of ventricular chamber development. Hepatic differentiation was dramatically but transiently retarded, yet is histologically and morphologically normal. These results ascribe an essential function for the RXR&agr; gene in embryonic development, and provide the first evidence of a requirement for RXR in one of its predicted hormone response pathways.
摘要翻译：根据本发明，提供了在至少一种特定组织类型中表达低于受体的类固醇/甲状腺超家族的至少一种成员的内源水平的功能突变小鼠的靶向丧失。例如，当培育成纯合子时，E13.5和E16.5之间的胚胎阶段，小鼠种系中RXRalpha基因的突变是致命的。负责这种致死作用的主要缺陷是心脏心室的发育不良，这表现为心室隔膜同时缺陷的严重变薄的心室壁。这种表型与胚胎维生素A缺乏症的一个亚组相同，因此在心脏形态发生中建立了RXRalpha作为维生素A信号通路的遗传成分。由神经嵴的衍生物填充并且对维生素A缺乏敏感的心脏流出道和相关血管在纯合胚中是正常的，表明心室发育的遗传独立性。肝分化显着但短暂延迟，但组织学和形态学正常。这些结果归因于胚胎发育中RXRalpha基因的基本功能，并提供了其预测的激素反应途径之一的RXR要求的第一个证据。

5. 发明授权

US09192601B2 Methods for enhancing muscle performance and tone 有权
标题翻译：增强肌肉功能和调理的方法
公开(公告)号：US09192601B2
公开(公告)日：2015-11-24
申请号：US12810123
申请日：2008-12-29
申请人： Ronald M. Evans , Vihang A. Narkar , Reuben J. Shaw , Michael Downes , Ruth T. Yu
发明人： Ronald M. Evans , Vihang A. Narkar , Reuben J. Shaw , Michael Downes , Ruth T. Yu
IPC分类号： A61K31/4178 , A61K31/426 , A61K31/47 , C12Q1/68
CPC分类号： A61K31/426 , A61K31/4178 , A61K31/47 , C12Q1/6876 , C12Q2600/136 , C12Q2600/158
摘要： Provided herein are methods and compositions for improving muscle performance and increasing endurance. Agonists of AMP-activated protein kinase (AMPK) and agonists of peroxisome proliferator-activated receptor delta (PPARδ) can be used in such treatments.
摘要翻译：本文提供了用于改善肌肉性能和增加耐力的方法和组合物。 AMP活化蛋白激酶（AMPK）的激动剂和过氧化物酶体增殖物激活受体δ（PPARδ）的激动剂可用于此类治疗。

6. 发明申请

US20130116171A1 METHODS FOR TREATING METABOLIC DISORDERS USING FGF 审中-公开
公开(公告)号：US20130116171A1
公开(公告)日：2013-05-09
申请号：US13641451
申请日：2011-04-18
申请人： Johan W. Jonker , Michael Downes , Ronald M. Evans , Jaemyoung Suh
发明人： Johan W. Jonker , Michael Downes , Ronald M. Evans , Jaemyoung Suh
IPC分类号： A61K38/18 , A61K45/06
CPC分类号： A61K38/1825 , A61K9/0019 , A61K31/4439 , A61K45/06 , A61K47/60 , A61K47/61 , A61K2300/00
摘要： The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.

7. 发明申请

US20110263454A1 Methods of Identifying Functional Characteristics of Promoters, Transcription Modifying Proteins and Transcription Modulating Agents 审中-公开
标题翻译：鉴定启动子，转录修饰蛋白和转录调节剂功能特征的方法
公开(公告)号：US20110263454A1
公开(公告)日：2011-10-27
申请号：US13061500
申请日：2009-08-28
申请人： Johan W. Jonker , Michael Downes , Ronald M. Evans
发明人： Johan W. Jonker , Michael Downes , Ronald M. Evans
IPC分类号： C40B30/06 , C40B60/12
CPC分类号： C12Q1/6897 , C12N15/1086
摘要： Provided herein is, inter alia, methods and compositions useful in therapeutic interrogation of complex physiologic pathways by massively parallel and permissive transcriptional screening. Thus, methods and compositions are provided herein that are useful for high-throughput functional analysis of complex, transcriptionally regulated physiological pathways. While examples are provided relating to nuclear receptors, the methods and composition can be generalized and applied to any class of transcription factor or any class of gene product that can regulate the activity of transcription. For example, in addition to nuclear receptors, the methods and compositions provided herein are generally applicable to all known transcription factors and any gene encoded product that modulates said transcription factor activity. Moreover, data obtained through the methods provided herein are directly comparable thereby facilitating high-throughput functional analysis.
摘要翻译：本文提供了通过大规模平行和允许的转录筛选在治疗性询问复杂生理学途径中有用的方法和组合物。因此，本文提供了可用于复杂的转录调节生理学途径的高通量功能分析的方法和组合物。虽然提供了与核受体相关的实例，但是该方法和组成可以被推广并应用于可以调节转录活性的任何类型的转录因子或任何类型的基因产物。例如，除了核受体之外，本文提供的方法和组合物通常可应用于调节所述转录因子活性的所有已知转录因子和任何基因编码产物。此外，通过本文提供的方法获得的数据是直接可比的，因此有助于高通量功能分析。

8. 发明申请

US20110014126A1 USE OF VITAMIN D RECEPTOR AGONISTS AND PRECURSORS TO TREAT FIBROSIS 有权
标题翻译：维生素D受体激动剂和前列腺素治疗纤维化的使用
公开(公告)号：US20110014126A1
公开(公告)日：2011-01-20
申请号：US12772981
申请日：2010-05-03
申请人： Ronald M. Evans , Michael Downes , Christopher Liddle , Nanthakumar Subramaniam , Caroline Flora Samer
发明人： Ronald M. Evans , Michael Downes , Christopher Liddle , Nanthakumar Subramaniam , Caroline Flora Samer
IPC分类号： A61K31/59 , A61P1/16 , C12Q1/02 , A61K49/00 , C12N5/071
CPC分类号： A61K31/00 , A61K31/592 , A61K31/593 , G01N33/5067 , G01N33/82 , G01N2800/085
摘要： This application relates to methods of treating, preventing, and ameliorating fibrosis, such as fibrosis of the liver. In particular, the application relates to methods of using a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors) for the treatment of liver fibrosis. Also disclosed are methods for screening for agents that treat, prevent, and ameliorate fibrosis.
摘要翻译：本申请涉及治疗，预防和改善纤维化（例如肝纤维化）的方法。特别地，本申请涉及使用维生素D受体激动剂（例如维生素D，维生素D类似物，维生素D前体和维生素D受体激动剂前体）用于治疗肝纤维化的方法。还公开了用于筛选治疗，预防和改善纤维化的药剂的方法。

9. 发明授权

US07647217B2 Structure of the farnesoid X receptor ligand binding domain and methods of use therefor 失效
标题翻译：法呢酯X受体配体结合域的结构及其用途
公开(公告)号：US07647217B2
公开(公告)日：2010-01-12
申请号：US10535042
申请日：2003-11-14
申请人： Michael R Downes , Mark A. Verdicia , Joseph P. Noel , Ronald M. Evans , Lindsey J. Bowman , Marianne Bowman
发明人： Michael R Downes , Mark A. Verdicia , Joseph P. Noel , Ronald M. Evans , Lindsey J. Bowman , Marianne Bowman
IPC分类号： G06G7/58 , C07K14/00
CPC分类号： C07K14/70567 , C07K2299/00 , G01N33/743 , G01N2500/00 , G06F19/16 , G06F19/706
摘要： The present invention provides compositions comprising the ligand binding domain (LBD) of a farnesoid X receptor (FXR) in crystalline form. In alternative embodiments, the LBD of FXR is complexed with a ligand therefor. There are provided high resolution structures of FXR complexed with a novel high affinity agonist, fexaramine. The discovered structure of a FXR LBD provides the first three-dimensional view of the structural basis for FXR ligand binding. The present invention further provides a computer for producing a three-dimensional representation of FXR or a complex thereof, and a computer for determining at least a portion of the structure coordinates of FXR or a complex thereof. The present invention further provides methods of using this structural information to predict molecules capable of binding to FXR; to identify compounds with agonist, antagonist or partial agonist activity for FXR; and to determine whether a test compound is capable of binding to the LBD of FXR. The present invention further provides compositions comprising compounds identified by such invention methods.
摘要翻译：本发明提供了包含结晶形式的法呢甾X受体（FXR）的配体结合结构域（LBD）的组合物。在替代实施方案中，FXR的LBD与其配体复合。提供了与新型高亲和力激动剂fexaramine复合的FXR的高分辨率结构。所发现的FXR LBD的结构提供了FXR配体结合的结构基础的第一个三维视图。本发明还提供一种用于产生FXR或其复数的三维表示的计算机，以及用于确定FXR的结构坐标的至少一部分或其复合体的计算机。本发明还提供使用该结构信息来预测能够结合FXR的分子的方法; 识别FXR激动剂，拮抗剂或部分激动剂活性的化合物; 并确定测试化合物是否能够结合FXR的LBD。本发明还提供包含通过本发明方法鉴定的化合物的组合物。

10. 发明授权

US07041498B2 Method for modulating processes mediated by farnesoid activated receptors 失效
公开(公告)号：US07041498B2
公开(公告)日：2006-05-09
申请号：US10155379
申请日：2002-05-24
申请人： Ronald M. Evans , Barry M. Forman , Cary A. Weinberger
发明人： Ronald M. Evans , Barry M. Forman , Cary A. Weinberger
IPC分类号： C12N5/00 , C12N15/24 , C07H17/00
CPC分类号： A61K31/045 , A61K31/202 , A61K31/22 , A61K31/336 , C07K14/70567 , G01N33/74 , G01N2333/70567
摘要： Farnesyl pyrophosphate, the metabolically active form of farnesol, is a key precursor in the synthesis of cholesterol, carotenoids, steroid hormones, bile acids and other molecules involved in cellular growth and metabolism. A nuclear receptor has been identified that is transcriptionally activated by farnesol and related molecules. This novel signaling pathway can be modulated by the use of key metabolic intermediates (or analogs and/or derivatives thereof) as transcriptional regulatory signals.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式